Most peptide drugs are given by injection. That means they must be manufactured under strict sterile conditions. Getting this right is critical. A contaminated injectable drug can seriously harm or kill a patient.
Fill-finish manufacturing is the process of putting the drug into its final container, whether that is a vial, prefilled syringe, or cartridge. Outsourcing this step to a specialist is common and smart. The equipment alone costs tens of millions of dollars, and running a sterile facility requires deep expertise.
- Peptide injectables require aseptic fill-finish processing because most peptides cannot survive terminal sterilization methods like heat or radiation.
- Outsourcing fill-finish to a specialist CDMO avoids tens of millions in equipment costs and leverages deep sterile manufacturing expertise.
- Lyophilization is often essential for peptide stability, so confirm your CDMO has integrated freeze-drying capacity before signing contracts.
- Request recent media fill results and FDA inspection history when evaluating any fill-finish CDMO for peptide manufacturing.
- Plan technology transfer timelines of six to twelve months minimum, as process validation and regulatory filings require significant lead time.
- Book fill-finish capacity well in advance since sterile manufacturing slots are limited and demand continues to grow industrywide.
What Is Fill-Finish Manufacturing?
Fill-finish is the last step in drug manufacturing. The drug product has already been formulated and filtered. Fill-finish puts it into its final container, seals it, inspects it, and labels it.
For peptide drugs, fill-finish almost always involves aseptic processing because most peptides cannot be terminally sterilized. Heat and radiation destroy peptide structure. So the drug must be kept sterile throughout the entire filling process.
This makes peptide fill-finish one of the most demanding operations in pharmaceutical manufacturing.
Thomas Ransohoff, Vice President at BioProcess Technology Consultants, wrote in Pharmaceutical Engineering (2023): "The shift toward complex biologics and peptides has made aseptic fill-finish capacity one of the most critical bottlenecks in the pharmaceutical supply chain."
Key Steps in Peptide Fill-Finish Manufacturing
Understanding the full process helps you ask the right questions when selecting a fill-finish partner.
| Step | Description |
|---|---|
| Bioburden reduction | Pre-filtration to reduce microbial load before sterile filtration |
| Sterile filtration | Drug solution is passed through a 0.22 micron filter |
| Container preparation | Vials, stoppers, or syringes are washed, depyrogenated, and sterilized |
| Filling | Drug is dispensed into containers using precision filling equipment |
| Stoppering/sealing | Containers are closed under inert gas to prevent oxidation |
| Lyophilization | If freeze-dried, vials go into the lyophilizer at this stage |
| Capping | Aluminum crimp caps are applied to vials |
| Visual inspection | Each unit is checked for particles and cosmetic defects |
| Labeling and packaging | Final labels and outer packaging are applied |
| Batch release testing | QC testing confirms the batch meets specifications |
A single failed media fill run can shut down a sterile filling line for weeks and cost a CDMO over $500,000 in lost production and remediation.
Aseptic Processing vs. Terminal Sterilization
Terminal sterilization means the drug is sterilized after it is filled into the container. This is the preferred method because it is more reliable. But most peptides cannot survive terminal sterilization.
Aseptic processing means every component (drug solution, containers, closures) is sterilized separately and then assembled in a sterile environment. This is more complex and has more risks, but it is the only option for most peptide drugs.
Aseptic processing must be performed in an ISO 5 environment, the cleanest air classification used in drug manufacturing. This requires specialized cleanrooms, personnel gowning, and continuous environmental monitoring.
The FDA requires media fill simulations (also called process simulation tests) for aseptic filling lines. These tests use growth media instead of drug to verify that the filling process does not introduce contamination. Any media fill failure can lead to a production shutdown.
Container Types for Peptide Injectables
The choice of container affects patient convenience, stability, and manufacturing complexity.
| Container Type | Description | Best For |
|---|---|---|
| Glass vials | Most common, multiple dose sizes | Clinical and commercial use |
| Prefilled syringes | Ready to inject, reduces preparation steps | Patient self-injection |
| Cartridges | Used with auto-injector pen devices | Chronic dosing conditions |
| Dual-chamber syringes | Lyophilized drug and diluent in one device | Unstable peptides |
| Ampoules | Sealed glass, single use | Very small volumes |
Prefilled syringes are growing in popularity for peptide drugs because they reduce dosing errors and support at-home use. However, they require special filling lines and have tighter compatibility requirements.
Lyophilization in Fill-Finish
Many peptide drugs are filled as liquids and then lyophilized (freeze-dried) inside the vials. This requires a lyophilizer that is part of the fill-finish line. After filling, vials are loaded into the lyophilizer on partially inserted stoppers.
The lyophilization cycle runs for 24 to 72 hours or more. When the cycle finishes, the vials are fully stoppered inside the lyophilizer under vacuum or inert gas before they exit the sterile zone.
Lyophilization adds complexity and cost to fill-finish. Not all fill-finish CDMOs have lyophilizers. Make sure your potential partner has the lyophilization capacity your program needs.
GMP Requirements for Peptide Fill-Finish
Every step of fill-finish manufacturing must comply with Good Manufacturing Practice (GMP) regulations. For sterile products, this means:
- FDA 21 CFR Part 211 (U.S. domestic manufacturing)
- EU GMP Annex 1 (sterile medicinal products)
- ICH Q7 for API manufacturing where relevant
Fill-finish CDMOs undergo regular FDA inspections. Before selecting a partner, ask for their most recent FDA inspection report (Form 483) and Establishment Inspection Report (EIR). Review any observations carefully.
FDA Annex 1 was revised in 2022 with stricter requirements for contamination control strategy. Fill-finish CDMOs must now have a written Contamination Control Strategy (CCS) documenting how they prevent contamination at every step.
Before signing any CDMO contract, request their last three FDA 483 inspection reports and ask specifically about observations related to aseptic technique, because sterile filling deficiencies are the number one cause of injectable drug recalls.
Environmental Monitoring in Aseptic Fill-Finish
Environmental monitoring (EM) is the continuous testing of air, surfaces, and personnel in the cleanroom. EM data proves that the sterile manufacturing environment is under control.
Key EM activities include:
- Air particle counts (ISO 5, 7, and 8 zone monitoring)
- Viable air sampling using impactors and settle plates
- Surface sampling using contact plates and swabs
- Personnel gown monitoring at entry and exit
Any out-of-limit EM result triggers an investigation. Repeated exceedances can cause production shutdowns and FDA warning letters. When evaluating a fill-finish CDMO, ask about their EM data trends and exceedance rates.
Selecting a Peptide Fill-Finish CDMO
Choosing the right fill-finish partner is a high-stakes decision. Here is what to evaluate. For additional context, the FDA guidance on contract manufacturing offers relevant guidance on this topic.
Regulatory track record is the first filter. How many FDA inspections have they passed? Have they had Warning Letters? What was the outcome? A clean regulatory history is non-negotiable.
Container type compatibility must match your product. Not all CDMOs can fill prefilled syringes or run lyophilization. Confirm their capability before going deeper in discussions.
Batch size flexibility matters for clinical programs. You may need very small batches (a few hundred vials) for Phase 1 trials. Confirm the CDMO can run small-scale batches without compromising quality.
Lead times and capacity are often overlooked. Fill-finish CDMOs are capacity-constrained. Ask about current booking status and expected availability for your timeline.
Peptide-specific experience is valuable. Ask about their experience with peptide adsorption, oxygen sensitivity, and lyophilization cycle development. A partner who has seen these issues before will handle them faster.
"The biggest risk in outsourcing fill-finish is assuming the CDMO is ready for your product. You must audit their facility and ask very specific questions about peptide handling." - VP Manufacturing, peptide drug developer
Typical Costs for Peptide Fill-Finish Manufacturing
Fill-finish costs depend on batch size, container type, and whether lyophilization is required.
| Service | Typical Cost Range |
|---|---|
| Tech transfer (one-time) | $50,000 to $250,000 |
| Clinical batch (vials, liquid) | $20,000 to $100,000 |
| Clinical batch (vials, lyophilized) | $50,000 to $200,000 |
| Commercial batch (vials, liquid) | $100,000 to $500,000+ |
| Prefilled syringe filling (clinical) | $30,000 to $150,000 |
These ranges are estimates. Actual costs vary significantly based on volume, complexity, and the specific CDMO's pricing model.
Technology Transfer to a Fill-Finish CDMO
Technology transfer is the process of moving your manufacturing process from your lab or previous CDMO to the new fill-finish partner. It is a critical and often underestimated step.
A good tech transfer package includes your batch records, analytical methods, process validation reports, and any known process sensitivities. The receiving CDMO uses this information to set up and qualify their process.
Expect 3 to 9 months for a complete tech transfer for a new peptide injectable product. Complex formulations or new container types take longer.
Securing fill-finish capacity early and verifying your CDMO's aseptic processing track record are the two decisions that most directly determine whether your peptide injectable reaches market on schedule.
FAQs
What is the difference between fill-finish and drug product manufacturing?
Drug product manufacturing covers everything from formulation through fill-finish to finished packaged goods. Fill-finish specifically refers to the filling and sealing step. However, many people use these terms interchangeably. When talking to a CDMO, clarify exactly which steps they will be responsible for.
Do I need to validate the fill-finish process before commercial manufacturing?
Yes. Process validation is required by FDA regulations before commercial distribution. It involves three consecutive batches that demonstrate the process consistently produces a product meeting its specifications. For clinical supplies, process validation is not required, but the process should be well-characterized.
How many vials can a fill-finish CDMO produce in one batch?
Clinical batch sizes for peptide drugs typically range from 500 to 5,000 vials. Commercial batches can range from 10,000 to over 1,000,000 vials depending on the drug's market size and dosing frequency. Confirm the CDMO's minimum and maximum batch sizes early in discussions.
What is a sterility test and how is it done?
A sterility test checks whether the drug product is free from microorganisms. It involves incubating samples from the batch in growth media and observing for any microbial growth over 14 days. A positive sterility test means the batch fails and cannot be used. Sterility testing is required for all injectable drug products.
How far in advance do I need to book fill-finish capacity?
Good fill-finish CDMOs with strong regulatory reputations are often booked 12 to 24 months in advance. For clinical programs, book your slot as soon as you have a reasonable confidence in your timeline. Missing a fill-finish slot can delay your trial by 6 to 12 months.
Find Expert Peptide Fill-Finish Manufacturing Partners
Finding a fill-finish CDMO with the right sterile capabilities, peptide experience, and clean regulatory history is not easy. It takes time and specialized knowledge to evaluate the right partners.
PeptideStaff connects peptide companies with vetted fill-finish CDMOs, sterile manufacturing specialists, and project managers who know how to run a successful tech transfer. We save you the time and reduce the risk of a costly wrong choice.
Ready to find your fill-finish manufacturing partner? Contact PeptideStaff today and let us connect you with the right sterile manufacturing experts.
Topics
Amanda Foster
Peptide Industry Analyst
MS, Health Economics | 8 years in peptide market research
Tracks workforce trends, compensation data, and market dynamics across the peptide industry. Produces quarterly salary benchmarks and employer-of-record analysis cited by clinic operators nationwide.
Reviewed by Amanda Foster, MS, April 2026